** Analysts at Jefferies downgrade rating to "hold" from "buy" on New Zealand's Fisher & Paykel Healthcare FPH.NZ
** Jefferies says it is interested in knowing the impacts FPH has faced from U.S. tariffs to date, when it reports FY25 results on May 28; to keep a close eye on co's mitigation strategies
** However, brokerage keeps PT unchanged at NZ$39.40 per share
** We understand the primary impact on FPH imports is currently a 10% tariff on New Zealand products — brokerage
** One of 12 analysts rate the stock "buy" or higher, nine "hold" and two "sell" or lower; their median PT is NZ$35.81, according to data compiled by LSEG
** Stock has fallen 4.3% this year, as of last close
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.